United posts positive data for inhaled PAH drug

United Therapeutics shares were on the rise after the company announced positive results from a Phase III trial of Viveta, an inhaled version of pulmonary arterial hypertension (PAH) drug Remodulin. Patients taking Viveta were able to walk farther in six minutes than those taking placebo. Analysts expect United to file an NDA sometime in June. If approved, Viveta will compete with Actelion's Ventavis, the only other inhaled PAH drug on the market.

- read the AP report

Suggested Articles

LianBio aims to bring much-needed new drugs to China and serve as a partner for U.S. biotechs looking to expand into Asia.

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.